Newer anti-obesity medications are being developed that have promise for altering energy expenditure, although these are multi-receptor agonists involving binding both GLP-1 receptors and receptors such as glucagon which has been associated with increased energy expenditure [104]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.